İlhami KİKİ, Nuri KÖSE, Mehmet GÜNDOĞDU, Hasan KAYA, Ramazan ÇETİNKAYA

RELATIONSHIP BETWEEN VON WILLEBRAND FACTOR ACTIVITY AND THERAPEUTIC SUCCESS OF THROMBOLYTIC THERAPY IN PATIENTS WITH MYOCARDIAL INFARCTION

Anahtar Kelimeler:

-

RELATIONSHIP BETWEEN VON WILLEBRAND FACTOR ACTIVITY AND THERAPEUTIC SUCCESS OF THROMBOLYTIC THERAPY IN PATIENTS WITH MYOCARDIAL INFARCTION

Aim: Von Willebrand Factor is a glycoprotein, which plays role in primary hemostasis, mainly acts getting platelets to adhere onto the subendothelial tissue and carrying Factor VIII. Although vWF deficient animals had been shown to be resistant to atherosclerosis and thrombotic events, it had not been proven in humans. In this study, we aimed to investigate whether a relationship exists between VWF activity and therapeutic success of thrombolysis. Methods: The study was carried out on 40 patients who were administered thrombolytic therapy due to myocardial infarction and 30 healthy controls. Von Willebrand Factor activity was measured in plasma samples which were taken before the procedure. The results were compared between therapy effective and ineffective patients and controls. Results: Average vWF activity was 131.0±64.0% in patients whereas 113.9±47.7% in controls (p>0.05). On the other hand, mean VWF activities of 24 patients who achieved therapeutic success and 16 therapy failed patients were 103.9±58.9% and 171.7±49.0% respectively (p

Keywords:

Von Willebrand Factor, myocardial infarction thrombolytic therapy,

PDF

___

1- Ginsburg D. Von Willebrand disease. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, editors. Williams Hematology. 6th Edition, Part X, Ch 135, New York: McGRAW – HILL. International Edition 2001: 1813-28
2- Antman EM, Braunwald E. ST-segment Elevation Myocardial Infarction. In Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds). Harrison’s Principles of Internal Medicine. 16th Edition, Part: VIII, Ch: 228, New York, McGRAW – HILL Co. 2005:1448-59
3- Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, editors. Williams Hematology. 6th Edition, Part X, Ch 130, New York: McGRAW – HILL. International Edition 2001:1743-61
4- Fuster V, Bowie EJ. The von Willebrand pig as a model for atherosclerosis research. Thromb Haemost 1978;39:322-7
5- Evrengul H, Celek T, Tanriverdi H, Kaftan A, Dursunoglu D, Kilic M. The effect of preinfarction angina on clinical reperfusion time in patients with acute myocardial infarction receiving successful thrombolytic therapy. Can J Cardiol 2005;21:915-20
6- Federici AB, Mannucci PM, Fogato E, Ghidoni P, Matturri L. Autopsy findings in three patients with von Willebrand disease type IIB and type III: presence of atherosclerotic lesions without occlusive arterial thrombi. Thromb Haemost 1993; 70:758-61
7- Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost. 2006; 4: 2490–2493
8- Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006;4:1186-93
9- Bongers TN, de Maat MP, van Goor ML, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke. 2006; 37: 2672-2677.
10- Uchiyama T, Matsumoto M, Kobayashi N. Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy. Thromb Res 1990;59:955-65
11- Yoo G, Blombäck M, Schenck-Gustafsson K, He S. Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetininduced platelet aggregation. Br J Haematol 2003;121:123-9
12- Andreotti F, Roncaglioni MC, Hackett DR, et al. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990;16: 1553-60
13- Andreotti F, Hackett DR, Haider AW, et al. Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction. Thromb Haemost 1992;68:678-82
14- Spaziani D, De Servi S, Morelli B, et al. Different patterns of interleukin-6 and von Willebrand factor antigen changes after coronary stenting in unstable versus stable angina. Ital Heart J 2002;3:593-7
15- Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995;92:31-8
16- Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand Factor predicts adverse outcome in unstable coronary artery disease beneficial effects of enoxaparin. Circulation 1998;98:294-9
17- De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity.J Endocrinol Invest 2002;25:899-904
18- Lichtman MA, Williams WJ. Hematology in the aged. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U editors. Williams Hematology. 6th Edition, Part II, Ch 8, New York: McGRAW – HILL. International Edition 2001:93-100
19- Strony J, Phillips M, Brands D, Moake J, Adelman B. Aurintricarboxylic acid in a canine model of coronary artery thrombosis. Circulation 1990;81:1106-14
20- Matsuno H, Kozawa O, Niwa M, Uematsu T. Inhibition of von Willebrand factor binding to platelet GPIb by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation 1997;96:1299- 304
21- Strony J, Song A, Rusterholtz L, Adelman B. Aurintricarboxylic acid prevents acute rethrombosis in a canine model of arterial thrombosis. Arterioscler Thromb Vasc Biol 1995;15:359-66
22- Kawasaki T, Kaku S, Kohinata T, et al. Inhibition by aurintricarboxylic acid of von Willebrand Factor binding to platelet GPIb, platelet retention, and thrombus formation in vivo. Am J Hematol. 1994; 47: 6-15